Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2015 1
2016 3
2017 2
2018 1
2019 3
2020 3
2021 8
2022 13
2023 18
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Results by year

Filters applied: . Clear all
Page 1
Application of blinatumomab, a bispecific anti-CD3/CD19 T-cell engager, in treating severe systemic sclerosis: A case study.
Subklewe M, Magno G, Gebhardt C, Bücklein V, Szelinski F, Arévalo HJR, Hänel G, Dörner T, Zugmaier G, von Bergwelt-Baildon M, Skapenko A, Schulze-Koops H. Subklewe M, et al. Among authors: bucklein v. Eur J Cancer. 2024 Apr 22;204:114071. doi: 10.1016/j.ejca.2024.114071. Online ahead of print. Eur J Cancer. 2024. PMID: 38691878
Friday Leukemia-a Structural Phenomenon.
Rausch C, Arnreich C, Rothenberg-Thurley M, Dufour A, Schneider S, Gittinger H, Bücklein V, Subklewe M, Sauerland C, Görlich D, Krug U, Berdel WE, Wörmann BJ, Hiddemann W, Braess J, von Bergwelt-Baildon M, Spiekermann K, Metzeler KH, Herold T. Rausch C, et al. Among authors: bucklein v. Dtsch Arztebl Int. 2024 Feb 9;121(3):94-95. doi: 10.3238/arztebl.m2023.0260. Dtsch Arztebl Int. 2024. PMID: 38471183 Free PMC article. No abstract available.
Combining venetoclax and azacytidine with T-cell bispecific antibodies for treatment of acute myeloid leukemia: a preclinical assessment.
Hänel G, Schönle A, Neumann AS, Nixdorf D, Philipp N, Sponheimer M, Leutbecher A, Emhardt AJ, Magno G, Bücklein V, Eckmann J, Dunshee D, Kramar V, Korfi K, Colombetti S, Umaña P, Klein C, Subklewe M. Hänel G, et al. Among authors: bucklein v. Leukemia. 2024 Feb;38(2):398-402. doi: 10.1038/s41375-023-02127-0. Epub 2024 Jan 11. Leukemia. 2024. PMID: 38212534 Free PMC article. No abstract available.
Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality.
Rejeski K, Wang Y, Hansen DK, Iacoboni G, Bachy E, Bansal R, Penack O, Müller F, Bethge W, Munoz J, Mohty R, Bücklein VL, Barba P, Locke FL, Lin Y, Jain MD, Subklewe M. Rejeski K, et al. Among authors: bucklein vl. Blood Adv. 2024 Apr 23;8(8):1857-1868. doi: 10.1182/bloodadvances.2023011767. Blood Adv. 2024. PMID: 38181508 Free PMC article.
Novel immunotherapies in the treatment of AML: is there hope?
Subklewe M, Bücklein V, Sallman D, Daver N. Subklewe M, et al. Among authors: bucklein v. Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):691-701. doi: 10.1182/hematology.2023000455. Hematology Am Soc Hematol Educ Program. 2023. PMID: 38066884
Functional connectivity MRI provides an imaging correlate for chimeric antigen receptor T-cell-associated neurotoxicity.
Stoecklein S, Wunderlich S, Papazov B, Winkelmann M, Kunz WG, Mueller K, Ernst K, Stoecklein VM, Blumenberg V, Karschnia P, Bücklein VL, Rejeski K, Schmidt C, von Bergwelt-Baildon M, Tonn JC, Ricke J, Liu H, Remi J, Subklewe M, von Baumgarten L, Schoeberl F. Stoecklein S, et al. Among authors: bucklein vl. Neurooncol Adv. 2023 Oct 24;5(1):vdad135. doi: 10.1093/noajnl/vdad135. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 38024243 Free PMC article.
Modification of Lugano criteria by pre-infusion tumor kinetics improves early survival prediction for patients with lymphoma under chimeric antigen receptor T-cell therapy.
Winkelmann M, Blumenberg V, Rejeski K, Quell C, Bücklein V, Ingenerf M, Unterrainer M, Schmidt C, Dekorsy FJ, Bartenstein P, Ricke J, von Bergwelt-Baildon M, Subklewe M, Kunz WG. Winkelmann M, et al. Among authors: bucklein v. J Immunother Cancer. 2023 Oct;11(10):e006659. doi: 10.1136/jitc-2022-006659. J Immunother Cancer. 2023. PMID: 37880181 Free PMC article.
Predictive value of pre-infusion tumor growth rate for the occurrence and severity of CRS and ICANS in lymphoma under CAR T-cell therapy.
Winkelmann M, Blumenberg V, Rejeski K, Quell C, Bücklein VL, Ingenerf M, Unterrainer M, Schmidt C, Dekorsy FJ, Bartenstein P, Ricke J, von Bergwelt-Baildon M, Subklewe M, Kunz WG. Winkelmann M, et al. Among authors: bucklein vl. Ann Hematol. 2024 Jan;103(1):259-268. doi: 10.1007/s00277-023-05507-9. Epub 2023 Oct 20. Ann Hematol. 2024. PMID: 37861736
Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R/R DLBCL.
Blumenberg V, Busch G, Baumann S, Jitschin R, Iacoboni G, Gallur L, Iraola-Truchuelo J, Hoster E, Winkelmann M, Hellwig K, Schmidt C, Frölich L, Tast B, Hildebrand F, Rejeski K, Dekorsy F, Schmidkonz C, Bäuerle T, Kunz WG, Mougiakakos D, Müller F, von Bergwelt-Baildon M, Barba P, Bücklein VL, Mackensen A, Völkl S, Subklewe M. Blumenberg V, et al. Among authors: bucklein vl. Blood Adv. 2023 Nov 28;7(22):6844-6849. doi: 10.1182/bloodadvances.2023010364. Blood Adv. 2023. PMID: 37748131 Free PMC article.
Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion.
Rejeski K, Perez A, Iacoboni G, Blumenberg V, Bücklein VL, Völkl S, Penack O, Albanyan O, Stock S, Müller F, Karschnia P, Petrera A, Reid K, Faramand R, Davila ML, Modi K, Dean EA, Bachmeier C, von Bergwelt-Baildon M, Locke FL, Bethge W, Bullinger L, Mackensen A, Barba P, Jain MD, Subklewe M. Rejeski K, et al. Among authors: bucklein vl. Sci Adv. 2023 Sep 22;9(38):eadg3919. doi: 10.1126/sciadv.adg3919. Epub 2023 Sep 22. Sci Adv. 2023. PMID: 37738350 Free PMC article.
56 results